NGS Assessment of Congenitally Deafned Children and Neonatal Deafness Screnning

Congenital Deafness Clinical Trial

— GHELP  

Official title:

Promote Personalized Medicine Based on Diagnostic Genomic Tools in Order to Innovate in the Early Detection of Child Deafness in the SUDOE Space (European International Project)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04350619
• Other study ID #: GHELP
• Status: Not yet recruiting
• Start date: April 30, 2020
• Est. completion date: April 2021

Study information

• Verified date: March 2020
• Source: Clinica Universidad de Navarra, Universidad de Navarra
• Contact: Manuel Jesús M Manrique Rodriguez, ENT
• Phone: 948255400
• Email: mmanrique[@]unav.es
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To assess the diagnostic value of NGS screnning in prelingually deafned children using a new designed chip, and to evaluate its interest in a the neonatal screening program for ddetecting congenitally deafned children.

Description:

The aim of the study is to evaluate the diagnostic value of a new panel of gene in NGS study in children presenting :

1. A congenitally deafness : it is a retrospective study in children aged 0 to 17 yrs with hearing thresholds over 40 dB in the best ear using adapted audiometric assessment,

2. A suspicion of deafness in babies aged 0 to 6 months having an abnormal response after otoacoustic emissions and automated ABR assessment.

The main outcomes studied will be the finding of a pathogenic mutation (or several mutations).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 220
• Est. completion date: April 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria:

• Retropective study

Inclusion criteria:

• Age of onset of deafness between 0 and 17 years

• With a hearing loss of one or two senses with, on the ear most affected, a hearing loss more than 40 dB in mean audiometric loss in behavioural audiometry

• Availability of detailed information in Appendix 1: History, history and course of disease, associated symptoms, otoscopy data, radiology, treatments and hearing aids implemented.

• Availability of DNA samples stored in an existing collection.

• Consent to participate in the study (non-opposition) by the legal representative

Exclusion Criteria:

• Exclusion criteria:

• Child with a known cause of observed deafness (meningitis, post-surgery or drug iatrogenic, trauma, infections, tumor)

• Family not willing to participate in the study

Prospective study

Inclusion criteria:

• Age of the child 0 to 6 months including corrected age having had on at least one of the two ears a lack of acoustic otoemissions and a lack of response in automated PEA, and a threshold of PEA at least on one ear at more than 40 dB.

• Availability of detailed information in Appendix 2: Personal history, family history of deafness, associated symptoms, tympanometry, otoscopy data, neonatal deafness test data.

• Collection of the consent of the legal representative

Exclusion criteria:

· Family not willing to participate in the study

Related Conditions & MeSH terms

• Congenital Deafness
• Deafness
• Hearing Loss
• Suspicion of Congenital Deafness

Intervention

Other:
• Genetic screening. No therapeutic intervention
Genetic screening using NGS technique. No therapeutic intervention

Locations

Country	Name	City	State
France	Chu Montpellier	Montpellier

Sponsors (8)

Lead Sponsor	Collaborator
Clinica Universidad de Navarra, Universidad de Navarra	Asociacion Instituto Biodonostia, Centro Hospitalar de Lisboa Central, DREAMgenics S.L., Hospital CUF Porto, S.A., Instituto de Salud Pública y Laboral de Navarra, University Hospital, Montpellier, University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of mutation	It will realized the extraction blood sample in the same day and clinical information will be collected also.	1 day
Secondary	Phenotyping the mutation	Clinical information for each patient will be define for the following variables: age and gender, medical antecedents, audiometric data, other syndromic syntomps, ear radiologic data and type of treatment for treating the hearing loss.	1 day